Mer­ck KGaA beefs up its mR­NA work with a $780M buy­out of a boom­ing play­er

Burst­ing at the seams and ex­e­cut­ing plans for swift ex­pan­sion to sup­port its man­u­fac­tur­ing work for the mR­NA vac­cine out of Pfiz­er/BioN­Tech, In­di­anapo­lis-based Ex­e­lead has now been scooped up in a $780 mil­lion cash buy­out deal.

Ger­many’s Mer­ck KGaA, which bought out an­oth­er mR­NA man­u­fac­tur­er, AmpTec, ear­ly last year, has been beef­ing up its ops around lipids, which, in mR­NA vac­cines, play a key role in turn­ing hu­man cells in­to a mi­ni vac­cine fac­to­ries.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER